Filter
3121
Text search:
adverse
health
effects
Featured
Recommendations
340
New Publications
754
Language
Document type
No document type
1636
Studies & Reports
535
Guidelines
534
Manuals
180
Strategic & Response Plan
101
Fact sheets
56
Training Material
45
Situation Updates
13
Infographics
7
Brochures
6
Resource Platforms
5
Videos
2
App
1
Countries / Regions
India
148
Global
136
Kenya
75
Western and Central Europe
72
South Africa
64
Ethiopia
61
Nepal
52
Uganda
51
Nigeria
47
Tanzania
41
Latin America and the Carribbean
40
Africa
39
Sierra Leone
37
Ghana
37
Zambia
35
Malawi
31
Philippines
29
Liberia
28
Myanmar / Burma
28
Bangladesh
27
Rwanda
23
Ukraine
23
South–East Asia Region
21
Zimbabwe
20
Namibia
19
Eastern Europe
19
Syria
18
Cambodia
17
Indonesia
15
East and Southern Africa
14
Asia
14
USA
12
Brazil
12
Guinea
11
South Sudan
11
Botswana
11
Eastern Europe and Central Asia
11
Senegal
10
Germany
10
Eswatini/ Swaziland
10
Congo, Democratic Republic of
9
Mozambique
9
Sudan
9
West and Central Africa
9
Middle East and North Africa
9
Russia
9
Thailand
8
Lesotho
8
Western Pacific Region
8
Burkina Faso
7
Yemen
6
Venezuela
6
Pakistan
5
Colombia
5
Moldova
5
Mali
4
Jordan
4
Afghanistan
4
China
4
Sri Lanka
4
Cameroon
3
Niger
3
Haiti
3
Somalia
3
Lebanon
3
Egypt
3
Madagascar
3
Laos
3
Iraq
2
Gambia
2
Singapore
2
Benin
2
Central African Republic
2
Argentina
2
North Macedonia
2
Ecuador
2
Angola
2
Chile
2
Paraguay
2
Palestine
2
Timor Leste/ East Timor
2
Tajikistan
2
Kyrgyzstan
2
Georgia
2
Vietnam
2
North America
2
Belarus
2
Guinea-Bissau
1
Côte d’Ivoire / Ivory Coast
1
Chad
1
Mauritania
1
Ireland
1
Papua New Guinea
1
Vanuatu
1
Peru
1
Burundi
1
Honduras
1
El Salvador
1
Greece
1
Guatemala
1
Other region
1
Fiji
1
Solomon Islands
1
Bhutan
1
Poland
1
Albania
1
Djibouti
1
Canada
1
Romania
1
Lithuania
1
Iran
1
Kazakhstan
1
Turkmenistan
1
United Kingdom
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
949
Clinical Guidelines
346
Public Health
182
Women & Child Health
182
Key Resources
171
Capacity Building
46
Pharmacy & Technologies
29
Toolboxes
Mental Health
349
COVID-19
244
TB
200
HIV
193
Planetary Health
181
Pharmacy
102
NTDs
101
NCDs
95
AMR
82
Caregiver
80
Ebola & Marburg
62
Conflict
62
Global Health Education
60
Refugee
53
Disability
48
Rapid Response
45
Malaria
44
Specific Hazards
37
Natural Hazards
35
2.0 Rapid Response
29
Zika
22
Health Financing Toolbox
20
Polio
14
Cholera
10
Social Ethics
5
Typhoon
2
For patients on HFNO with persistent hypoxaemia or respiratory distress:
• Check the equipment: inspect the exterior of the machine, the tubing (circuit), the prong for any sign of mechanical damage, confirm it fits and the filters are in place. Ensure the settings are appropriate and flow is max
...
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
Guidance for health workers
Q7: What is the effectiveness, safety and role of pharmacological and non-pharmacological interventions, within non- specialist health care for children with a diagnosis of Attention-deficit hyperactivity disorder (ADHD)?
Biweekly situation reports
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
WHO Living guideline: Drugs to prevent COVID-19
recommended
Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform
...
A handbook for district and health facility staff
A systematic review of randomized controlled efficacy trials | REPORT -
DEPARTMENT OF CHILD AND ADOLESCENT HEALTH AND DEVELOPMENT
Q8. SCOPING QUESTION: In people with bipolar disorders who require maintenance treatment, are a) antipsychotics or b) mood stabilizers (lithium, valproate or carbamazepine) effective and safe?
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?